Data / Drug companies / Nicotine transdermal system
Nicotine transdermal system: 10 companies and 33 products in the FDA NDC directory
Nicotine transdermal system is listed in the FDA National Drug Code Directory by 10 companies, with 33 products in commercial distribution. 33 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are patch, extended release; patch, and the newest product started marketing on May 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 33
- Generic (ANDA) products
- 33 (100.0%)
- Application numbers
- 1
- Routes
- Transdermal
- Brand names
- Foster and Thrive Step 2, Foster and Thrive Step 3, Foster and Thrive Step 1
- openFDA record search
- api.fda.gov
Companies that list nicotine transdermal system
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Aveva Drug Delivery Systems Inc. | 6 | patch | Generic drugs (ANDA) | November 24, 2025 |
| Amerisource Bergen | 4 | patch, extended release | Generic drugs (ANDA) | June 25, 2024 |
| BluePoint Laboratories | 3 | patch, extended release | Generic drugs (ANDA) | June 22, 2020 |
| Cardinal Health 110, LLC. DBA Leader | 3 | patch, extended release | Generic drugs (ANDA) | September 1, 2024 |
| Ingenus Pharmaceuticals, LLC | 3 | patch | Generic drugs (ANDA) | May 19, 2026 |
| Quitine LLC | 3 | patch | Generic drugs (ANDA) | March 26, 2026 |
| Strategic Sourcing Services LLC | 3 | patch | Generic drugs (ANDA) | June 25, 2024 |
| Topco Associates LLC | 3 | patch, extended release | Generic drugs (ANDA) | June 25, 2024 |
| Walgreen Company | 3 | patch, extended release | Generic drugs (ANDA) | September 30, 2024 |
| H E B | 2 | patch, extended release | Generic drugs (ANDA) | June 25, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch, extended release | 18 | 54.5% |
| Patch | 15 | 45.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 33 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Cholinergic Nicotinic Agonist | 33 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.